St. Clair Advisors LLC Makes New Investment in Bristol-Myers Squibb (NYSE:BMY)

St. Clair Advisors LLC acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 6,000 shares of the biopharmaceutical company's stock, valued at approximately $339,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of BMY. Transce3nd LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $28,000. Fairway Wealth LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Comprehensive Financial Planning Inc. PA purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at approximately $34,000. Tacita Capital Inc acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $39,000. Finally, M Holdings Securities Inc. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $39,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded down $0.01 during trading hours on Thursday, hitting $46.99. 11,034,958 shares of the stock were exchanged, compared to its average volume of 13,183,407. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market capitalization of $95.63 billion, a P/E ratio of -10.63, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The business's 50-day moving average is $52.31 and its two-hundred day moving average is $55.83.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period last year, the firm earned ($4.40) earnings per share. The business's revenue for the quarter was down 5.6% on a year-over-year basis. Equities research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a $0.62 dividend. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.28%. Bristol-Myers Squibb's payout ratio is presently 92.88%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on BMY shares. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Jefferies Financial Group decreased their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Citigroup upped their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Finally, UBS Group dropped their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.07% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.